Cara Therapeutics (CARA) Misses Q4 EPS by 33c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.81), $0.33 worse than the analyst estimate of ($0.48). "The Company did not recognize any revenues during the fourth quarter of 2016 or 2015."

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance